City-based contract research organisation, GVK Biosciences, is contemplating either acquiring a company or setting up its drug research and development (R&D) centre in Maryland, a state located in the mid-Atlantic region of the US.
“We cannot comment on the specifics. They (GVK Bio) just said that this was something that they were looking for in Maryland. We are more than happy to help in making such a transaction work, which encourages investments into Maryland,” Martin Joseph O’Malley, governor of Maryland, told Business Standard.
With Maryland being one of the top-2 destinations in the US for lifesciences and biotechnology, GVK Bio could find tremendous opportunities for entering the US market either through acquisition of Maryland companies or establishing their own location there, he said.